This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research
Liming Tang
The Affiliated Changzhou NO.2 People’s Hospital of Nanjing Medical University
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Latent transforming growth factor β binding protein 2 (LTBP2) involved in the TGF pathway to induce immunosuppression and immune response. However, the association between the outcome of patients, the infiltrating immune cell and LTBP2 expression is still unclear in human cancers. The LTBP2 expression was analyzed by TIIMER and Oncomine database. Based on the Prognoscan database, the GEPIA database, and the Kaplan-Meier plotter database, the prognostic value was assessed. The immune and stromal score of tumors was calculated through ESTIMATE. We additionally explore the relationship among the LTBP2 expression, the infiltrating immune cells, and its gene markers in the TIMER, TISIDB, and GEPIA database, the enriched KEGG pathways of LTBP2 were evaluated by GSEA. The result showed that LTBP2 expressed differently among the normal and tumor tissues in various sorts of cancer involving stomach adenocarcinoma (STAD) and colon adenocarcinoma (COAD), and three cohorts of COAD presented that the LTBP2 high expression was linked with poorer disease-free survival and the elevated LTBP2 expression correlated with progression-free survival and poorer overall survival in STAD. The LTBP2 was correlated with the stromal and immune score in different cancers. The infiltrating immune cells include the CD8+T cells and CD4+T cells, macrophages, neutrophils, and dendritic cells were correlated with the LTBP2 expression. Meanwhile, LTBP2 was related to the infiltrating immune cell’s gene markers and enriched immune-related pathways in STAD and COAD. LTBP2 was the potential to be an independent predictor for the prognosis and a new target for immunotherapy in STAD and COAD.
Keywords
LTBP2, stomach adenocarcinoma, colon adenocarcinoma, immune infiltration, prognosis.
This is a list of supplementary files associated with this preprint. Click to download.
- SupplementaryFigure1a.png
Supplementary Fig. 1. Correlation of LTBP2 expression with prognostic values in diverse types of cancer in the GEPIA databases. Overall survival and disease free curves comparing the high and low expression of LTBP2 in Adrenocortical carcinoma (ACC) (a–b), Bladder Urothelial Carcinoma (BLCA) (c–d), Breast invasive carcinoma (BRCA) (e–f), Cholangiocarcinoma (CHOL) (g–h), Colon adenocarcinoma (COAD) (i–j), Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) (k–l), Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (DLBC) (m–n), Esophageal carcinoma (ESCA) (o–p), Glioblastoma multiforme (GBM) (q–r) ,Head and Neck squamous cell carcinoma (HNSC) (s–t), Kidney Chromophobe (KICH) (u–v), Kidney renal clear cell carcinoma (KIRC) (w–x), Kidney renal papillary cell carcinoma (KIRP) (y–z), Acute Myeloid Leukemia (LAML) (aa–ab), Brain Lower Grade Glioma (LGG) (ac–ad), Liver hepatocellular carcinoma (LIHC) (ae–af), Lung adenocarcinoma (LUAD) (ag–ah), Lung squamous cell carcinoma (LUSC) (ai–aj), Mesothelioma (MESO) (ak–al), Ovarian serous cystadenocarcinoma (OV) (am–an), Pancreatic adenocarcinoma (PAAD) (ao–ap), Pheochromocytoma and Paraganglioma (PCPG) (aq–ar), Prostate adenocarcinoma (PRAD) (as–at), Rectum adenocarcinoma (READ) (au–av), Sarcoma (SARC) (aw–ax), Skin Cutaneous Melanoma (SKCM) (ay–az), Stomach adenocarcinoma (STAD) (ba–bb), Testicular Germ Cell Tumors (TGCT) (bc–bd), Thyroid carcinoma (THCA) (be–bf), Thymoma (THYM) (bg–bh), Uterine Corpus Endometrial Carcinoma (UCEC) (bi–bj), Uterine Carcinosarcoma (UCS) (bk–bl), Uveal Melanoma (UVM) (bm–bn).
- SupplementaryFigure1b.png
- SupplementaryFigure1c.png
- SupplementaryFigure2a.png
Supplementary Fig. 2. Correlation of LTBP2 expression with immune infiltration levels in diverse types of cancer in the TIMER database. Adrenocortical carcinoma (ACC) (a), Bladder Urothelial Carcinoma (BLCA) (b), Breast invasive carcinoma (BRCA) (c), Breast invasive carcinoma-Basal (BRCA-Basal) (d), Breast invasive carcinoma-Her2 (BRCA-Her2) (e), Breast invasive carcinoma-Luminal (BRCA- Luminal) (f), Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) (g), Cholangio carcinoma (CHOL) (h), Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (DLBC) (i), Esophageal carcinoma (ESCA) (j), Glioblastoma multiforme (GBM) (k) ,Head and Neck squamous cell carcinoma (HNSC) (l), Head and Neck squamous cell carcinomaHPVpos (HNSC-HPVpos) (m), Head and Neck squamous cell carcinoma-HPVneg (HNSC-HPVneg) (n), Kidney renal clear cell carcinoma (KIRC) (o), Kidney renal papillary cell carcinoma (KIRP) (p), Brain Lower Grade Glioma (LGG) (q), Liver hepatocellular carcinoma (LIHC) (r), Lung adenocarcinoma (LUAD) (s), Lung squamous cell carcinoma (LUSC) (t), Mesothelioma (MESO) (u), Ovarian serous cystadenocarcinoma (OV) (v), Pancreatic adenocarcinoma (PAAD) (w), Pheochromocytoma and Paraganglioma (PCPG) (x), Prostate adenocarcinoma (PRAD) (y), Rectum adenocarcinoma (READ) (z), Sarcoma (SARC) (aa), Skin Cutaneous Melanoma (SKCM) (ab), Skin Cutaneous Melanoma-Primary (SKCM-Primary) (ac), Skin Cutaneous Melanoma-Metastasis (SKCM- Metastasis) (ad), Testicular Germ Cell Tumors (TGCT) (ae), Thyroid carcinoma (THCA) (af), Thymoma (THYM) (ag), Uterine Corpus Endometrial Carcinoma (UCEC) (ah), Uterine Carcinosarcoma (UCS) (ai), Uveal Melanoma (UVM) (aj).
- SupplementaryFigure2b.png
- SupplementaryFigure2c.png
- SupplementaryFigure2d.png
- Supplementarytable1.docx
- Supplementarytable2.docx
- Supplementarytable3.docx
- Supplementarytable4.docx
- Supplementarytable5.docx
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 07 May, 2021
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Biomedical Engineering
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research
Liming Tang
The Affiliated Changzhou NO.2 People’s Hospital of Nanjing Medical University
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 07 May, 2021
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Biomedical Engineering
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Latent transforming growth factor β binding protein 2 (LTBP2) involved in the TGF pathway to induce immunosuppression and immune response. However, the association between the outcome of patients, the infiltrating immune cell and LTBP2 expression is still unclear in human cancers. The LTBP2 expression was analyzed by TIIMER and Oncomine database. Based on the Prognoscan database, the GEPIA database, and the Kaplan-Meier plotter database, the prognostic value was assessed. The immune and stromal score of tumors was calculated through ESTIMATE. We additionally explore the relationship among the LTBP2 expression, the infiltrating immune cells, and its gene markers in the TIMER, TISIDB, and GEPIA database, the enriched KEGG pathways of LTBP2 were evaluated by GSEA. The result showed that LTBP2 expressed differently among the normal and tumor tissues in various sorts of cancer involving stomach adenocarcinoma (STAD) and colon adenocarcinoma (COAD), and three cohorts of COAD presented that the LTBP2 high expression was linked with poorer disease-free survival and the elevated LTBP2 expression correlated with progression-free survival and poorer overall survival in STAD. The LTBP2 was correlated with the stromal and immune score in different cancers. The infiltrating immune cells include the CD8+T cells and CD4+T cells, macrophages, neutrophils, and dendritic cells were correlated with the LTBP2 expression. Meanwhile, LTBP2 was related to the infiltrating immune cell’s gene markers and enriched immune-related pathways in STAD and COAD. LTBP2 was the potential to be an independent predictor for the prognosis and a new target for immunotherapy in STAD and COAD.
This is a list of supplementary files associated with this preprint. Click to download.
- SupplementaryFigure1a.png
Supplementary Fig. 1. Correlation of LTBP2 expression with prognostic values in diverse types of cancer in the GEPIA databases. Overall survival and disease free curves comparing the high and low expression of LTBP2 in Adrenocortical carcinoma (ACC) (a–b), Bladder Urothelial Carcinoma (BLCA) (c–d), Breast invasive carcinoma (BRCA) (e–f), Cholangiocarcinoma (CHOL) (g–h), Colon adenocarcinoma (COAD) (i–j), Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) (k–l), Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (DLBC) (m–n), Esophageal carcinoma (ESCA) (o–p), Glioblastoma multiforme (GBM) (q–r) ,Head and Neck squamous cell carcinoma (HNSC) (s–t), Kidney Chromophobe (KICH) (u–v), Kidney renal clear cell carcinoma (KIRC) (w–x), Kidney renal papillary cell carcinoma (KIRP) (y–z), Acute Myeloid Leukemia (LAML) (aa–ab), Brain Lower Grade Glioma (LGG) (ac–ad), Liver hepatocellular carcinoma (LIHC) (ae–af), Lung adenocarcinoma (LUAD) (ag–ah), Lung squamous cell carcinoma (LUSC) (ai–aj), Mesothelioma (MESO) (ak–al), Ovarian serous cystadenocarcinoma (OV) (am–an), Pancreatic adenocarcinoma (PAAD) (ao–ap), Pheochromocytoma and Paraganglioma (PCPG) (aq–ar), Prostate adenocarcinoma (PRAD) (as–at), Rectum adenocarcinoma (READ) (au–av), Sarcoma (SARC) (aw–ax), Skin Cutaneous Melanoma (SKCM) (ay–az), Stomach adenocarcinoma (STAD) (ba–bb), Testicular Germ Cell Tumors (TGCT) (bc–bd), Thyroid carcinoma (THCA) (be–bf), Thymoma (THYM) (bg–bh), Uterine Corpus Endometrial Carcinoma (UCEC) (bi–bj), Uterine Carcinosarcoma (UCS) (bk–bl), Uveal Melanoma (UVM) (bm–bn).
- SupplementaryFigure1b.png
- SupplementaryFigure1c.png
- SupplementaryFigure2a.png
Supplementary Fig. 2. Correlation of LTBP2 expression with immune infiltration levels in diverse types of cancer in the TIMER database. Adrenocortical carcinoma (ACC) (a), Bladder Urothelial Carcinoma (BLCA) (b), Breast invasive carcinoma (BRCA) (c), Breast invasive carcinoma-Basal (BRCA-Basal) (d), Breast invasive carcinoma-Her2 (BRCA-Her2) (e), Breast invasive carcinoma-Luminal (BRCA- Luminal) (f), Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) (g), Cholangio carcinoma (CHOL) (h), Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (DLBC) (i), Esophageal carcinoma (ESCA) (j), Glioblastoma multiforme (GBM) (k) ,Head and Neck squamous cell carcinoma (HNSC) (l), Head and Neck squamous cell carcinomaHPVpos (HNSC-HPVpos) (m), Head and Neck squamous cell carcinoma-HPVneg (HNSC-HPVneg) (n), Kidney renal clear cell carcinoma (KIRC) (o), Kidney renal papillary cell carcinoma (KIRP) (p), Brain Lower Grade Glioma (LGG) (q), Liver hepatocellular carcinoma (LIHC) (r), Lung adenocarcinoma (LUAD) (s), Lung squamous cell carcinoma (LUSC) (t), Mesothelioma (MESO) (u), Ovarian serous cystadenocarcinoma (OV) (v), Pancreatic adenocarcinoma (PAAD) (w), Pheochromocytoma and Paraganglioma (PCPG) (x), Prostate adenocarcinoma (PRAD) (y), Rectum adenocarcinoma (READ) (z), Sarcoma (SARC) (aa), Skin Cutaneous Melanoma (SKCM) (ab), Skin Cutaneous Melanoma-Primary (SKCM-Primary) (ac), Skin Cutaneous Melanoma-Metastasis (SKCM- Metastasis) (ad), Testicular Germ Cell Tumors (TGCT) (ae), Thyroid carcinoma (THCA) (af), Thymoma (THYM) (ag), Uterine Corpus Endometrial Carcinoma (UCEC) (ah), Uterine Carcinosarcoma (UCS) (ai), Uveal Melanoma (UVM) (aj).
- SupplementaryFigure2b.png
- SupplementaryFigure2c.png
- SupplementaryFigure2d.png
- Supplementarytable1.docx
- Supplementarytable2.docx
- Supplementarytable3.docx
- Supplementarytable4.docx
- Supplementarytable5.docx
Loading...